A randomized phase III trial in patients with recurrent platinum sensitive ovarian cancer comparing efficacy and safety of paclitaxel micellar and Cremophor EL-paclitaxel.

CONCLUSION: Paclitaxel micellar (+ carboplatin) is non-inferior to Cr-EL paclitaxel (+ carboplatin) in terms of PFS and OS in the studied population. It provides a treatment option of a higher paclitaxel dose with a shorter infusion time without mandatory premedication. TRIAL REGISTRATION NUMBER: 2008-002668-32 (EudraCT), NCT00989131 (ClinicalTrials.gov). PMID: 31826802 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31826802?dopt=Abstract

Source: Gynecologic Oncology - December 8, 2019 Category: Cancer & Oncology Authors: Vergote I, Bergfeldt K, Franquet A, Lisyanskaya AS, Bjermo H, Heldring N, Buyse M, Brize A Tags: Gynecol Oncol Source Type: research